Structure-Based Design of small macrocyclic CDK9 degraders as chemical biology tools and beyond

With small macrocyclic “probes” from our proprietary library in the low nanomolar range IC50, we turned our attention to CDK9 inhibitors with good selectivity profile against CDK1/2/5/7 as a starting point for building bifunctional small macrocyclic kinase degraders.

Animal models for novel therapies on fibrosis and NASH

Discovery of Novel Inhibitors of PIM-1 Kinase Enabled by Generative AI

Use generative AI to generate and identify new PIM-1 kinase inhibitor hits with activity, freedom-to-operate, and good in vitro ADME properties.

Pharmacokinetic and Biodistribution of Formatted Affimer® Biotherapeutics Targeting PD-L1

Programmed Cell Death-Ligand 1 (PD-L1) is part of the immune checkpoint system involved in preventing autoimmunity. PD-L1 is upregulated on tumors cells and binds to its receptor, PD-1, expressed by immune cells in the tumor microenvironment.

Tumor-specific molecular changes in luminal B breast cancer patient-derived xenografts (PDXs) with acquired resistance to endocrine treatment

In this study we describe establishment of a luminal breast cancer PDX model with acquired resistance to hormonotherapy

Development of an immunogenicity assay for Anti-Drug Antibody (ADA) detection directed against an oligonucleotide CpG D35 using ECL technology (MSD)

mAb formulation development and stability studies through complementary and orthogonal analytical methods

Live Biotherapeutic MRx0518 as a modulator of immune responses in intestinal tissue and breast tumor microenvironment

Modelling liver diseases from acute and chronic injury to hepatocellular carcinoma for development of new treatments

ADCs optimization led to a significant anti-tumoral activity in lymphoma and breast tumor xenograft mouse models

NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA

NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA